Australia's Algorae Pharmaceuticals gains after positive drug assessment
29/11/2024 02:27
** Shares of Algorae Pharmaceuticals 1AI.AX rise as much
14.35 to A$0.008, their highest levels since Nov 21
** The pharma co says it received positive outcomes from
pre-clinical studies for drug candidate AI-168
** Says drug demonstrates "statistically significant"
cardio-protective qualities
** Stock on track for second straight session of gains
** Over 9.6 mln shares change hands, compared with the
30-day average volume of 1.4 mln
** 1AI stock down 20% YTD
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))
Recent news on Algorae Pharmaceuticals
See all newsBrief: Algorae Pharmaceuticals Executes License & Supply Agreement With Torrent Pharma
Brief: Algorae Pharmaceuticals And Zydus Enter Exclusive Commercial Agreement
Brief: Algorae Pharmaceuticals Raises A$3.9 Million At A$0.012 Per Share
Brief: Algorae Pharmaceuticals Says TGA Accepts Initial Registration Dossier For Evaluation
Brief: Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program